{
    "clinical_study": {
        "@rank": "107624", 
        "arm_group": {
            "arm_group_label": "EPI-743", 
            "arm_group_type": "Experimental", 
            "description": "EPI-743, oral, 400mg three times daily for 3 months"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effects of EPI-743 in patients with\n      Friedreich's Ataxia point mutations"
        }, 
        "brief_title": "EPI-743 in Friedreich's Ataxia Point Mutations", 
        "condition": "Friedreich's Ataxia Point Mutation", 
        "condition_browse": {
            "mesh_term": [
                "Ataxia", 
                "Friedreich Ataxia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Diagnosis of genetically confirmed Friedreich's ataxia point mutation.\n\n          2. Visual acuity at baseline more than 15 letters on high contrast EDTRS at four meters.\n\n          3. FARS score of 20 to 90.\n\n          4. Male or female between 18 and 65 years of age.\n\n          5. Agreement to use contraception if within reproductive years\n\n          6. Hormone replacement therapy, if used, must remain stable for the duration of the\n             study.\n\n          7. Willingness and ability to comply with study procedures.\n\n          8. Willingness and ability to arrive at study site metropolitan area day prior to\n             evaluations.\n\n          9. Abstention from use of dietary supplements and non-prescribed medications at least 30\n             days prior to initiation of treatment and for the duration of the study. This would\n             specifically include idebenone, Coenzyme Q10 and vitamin E.\n\n         10. Abstention from foods or beverages or bars fortified with Coenzyme Q10, vitamin E,\n             super fortified functional foods or beverages at least 30 days prior to initiation of\n             treatment and for the duration of the study.\n\n         11. Abstention from use of other investigative or non-approved drugs within 30 days of\n             enrollment and for the duration of the study.\n\n         12. Subject can swallow multiple size 0 capsules.\n\n         13. Subject has voluntarily signed an IRB approved informed consent form to participate\n             in the study after all relevant aspects of the study have been explained and\n             discussed with the subject.\n\n        Exclusion Criteria:\n\n          1. Allergy to EPI-743 or sesame oil or nuts.\n\n          2. Clinically significant bleeding condition or abnormal PT/PTT INR (INR > two; PTT >\n             two-times normal).\n\n          3. Liver insufficiency with LFTs greater than three-times upper normal limit at\n             screening.\n\n          4. Renal insufficiency with creatinine > 1.5 at screening.\n\n          5. Fat malabsorption syndromes.\n\n          6. Any other respiratory chain diseases of the mitochondria or inborn errors of\n             metabolism.\n\n          7. Any other ophthalmologic conditions.\n\n          8. Clinically significant cardiomyopathy with ejection fraction < 40 percent at\n             screening.\n\n          9. Clinically significant arrhythmia within past two years requiring treatment.\n\n         10. Surgery planned through the duration of the study, including follow-up.\n\n         11. Pregnancy or breastfeeding.\n\n         12. Anticoagulant therapy within 30 days of enrollment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "4", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01962363", 
            "org_study_id": "EPI-743 PM"
        }, 
        "intervention": {
            "arm_group_label": "EPI-743", 
            "intervention_name": "EPI-743", 
            "intervention_type": "Drug", 
            "other_name": "Vincerinone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33612"
                }, 
                "name": "University of South Florida"
            }, 
            "investigator": {
                "last_name": "Theresa Zesiewicz, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2A Clinical Trial of EPI-743 (Vincerinone\u2122) on Visual Function in Friedreich's Ataxia Patients With Point Mutations", 
        "overall_contact": {
            "email": "kbarber@health.usf.edu", 
            "last_name": "Kelly Sullivan, PhD", 
            "phone": "813-974-5909"
        }, 
        "overall_contact_backup": {
            "email": "kalliso1@health.usf.edu", 
            "last_name": "Kevin Allison, BS", 
            "phone": "813-974-5909"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Low contrast acuity", 
                "measure": "Visual function", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Clinical and laboratory safety parameters", 
                "measure": "Safety parameters", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01962363"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Visual fields as assessed by Humphrey 30-2 exam; High contrast visual acuity", 
                "measure": "Visual function", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Friedreich's Ataxia Rating Scale", 
                "measure": "Neurologic function", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "25-foot walk (for subjects capable of completing the test on enrollment);", 
                "measure": "Physical function", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Patient report via rating scale", 
                "measure": "Health related quality of life", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Patient report via rating scale", 
                "measure": "Activities of Daily Living", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Echocardiogram", 
                "measure": "Cardiac indices", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "9 hole peg test", 
                "measure": "Upper extremity function", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Glutathione cycle components", 
                "measure": "Disease biomarkers", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "source": "University of South Florida", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Edison Pharmaceuticals Inc", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Friedreich's Ataxia Research Alliance", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of South Florida", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}